Indications for Use is a formal statement that precisely defines the patient population, target disease or condition, anatomical site, and clinical context for which a medical device is validated and intended to be utilized. This statement is a critical component of a device's regulatory submission, legally binding the manufacturer to market the device only for the specific, cleared purposes.
Glossary
Indications for Use
A precise description of the patient population, anatomical site, disease or condition, and clinical context for which a medical device is validated and cleared by regulatory bodies.
REGULATORY DEFINITION
What is Indications for Use?
A precise description of the patient population, anatomical site, and clinical context for which a medical device is validated.
Distinct from the broader Intended Use Statement, which defines a device's general purpose, the Indications for Use provides granular clinical parameters. It typically specifies the target anatomy, pathology, patient demographics, and the device's role in the clinical pathway, such as screening, diagnosis, or monitoring. Any off-label use by a physician is not covered by the manufacturer's cleared indications.
REGULATORY FRAMEWORK
Key Components of an Indications for Use Statement
The Indications for Use statement is a precise, structured declaration that defines the exact clinical context in which a medical device has been validated. It serves as the legal boundary for marketing claims and directly informs the FDA's review pathway.
01
Target Patient Population
Defines the specific demographic and clinical characteristics of the intended patient group.
- Age range: e.g., adults aged 22 and older
- Sex/gender: e.g., female patients
- Clinical condition: e.g., patients presenting with chest pain
- Exclusion criteria: e.g., patients with prior coronary bypass surgery
This component ensures the device is only marketed for populations where safety and effectiveness have been demonstrated.
02
Anatomical Site of Analysis
Specifies the exact body part or physiological system the device analyzes or treats.
- Organ or structure: e.g., the left ventricle of the heart
- Tissue type: e.g., cortical bone of the proximal femur
- Imaging plane: e.g., axial CT slices of the chest
Precision here is critical; a device cleared for the brain cannot be marketed for the liver without additional validation.
03
Clinical Context and Intended Use
Describes the specific clinical scenario, including the device's role in the diagnostic or therapeutic pathway.
- Screening vs. diagnostic: e.g., as an aid to primary diagnosis
- Triage setting: e.g., for use in the emergency department
- Adjunctive role: e.g., as a concurrent reading aid alongside a radiologist
This component distinguishes between first-reader, second-reader, and triage devices, each carrying different regulatory expectations.
04
Output and Clinical Actionability
States precisely what the device produces and how a clinician should interpret or act on that output.
- Output type: e.g., a probability score for malignancy
- Actionable result: e.g., flags cases for prioritized review
- Non-actionable output: e.g., provides a segmentation overlay without diagnostic recommendation
Devices that provide definitive diagnostic outputs face higher scrutiny than those offering measurement tools or visualization aids.
05
Limitations and Contraindications
Explicitly states the boundaries of validated performance and scenarios where the device must not be used.
- Technical limitations: e.g., not validated on images with severe motion artifact
- Clinical contraindications: e.g., not intended for pediatric patients
- Image quality requirements: e.g., requires 1.5T or 3T MRI scans with slice thickness ≤ 3mm
These statements protect both the manufacturer and patients by preventing off-label use in unvalidated contexts.
06
Relationship to Predicate Device Claims
For 510(k) submissions, the Indications for Use must align with or be narrower than the predicate device's cleared indications.
- Substantial equivalence: The IFU cannot introduce new intended uses not present in the predicate
- Narrowing is acceptable: e.g., restricting from 'all adults' to 'adults aged 40-75'
- Expansion requires De Novo or PMA: Adding a new anatomical site or clinical indication triggers a different pathway
This alignment is the foundation of the substantial equivalence argument in premarket notifications.
REGULATORY DISTINCTIONS
Indications for Use vs. Intended Use
A comparison of the two foundational statements required for FDA medical device submissions, clarifying their distinct regulatory purposes, scope, and content requirements.
| Feature | Indications for Use | Intended Use |
|---|---|---|
Regulatory Definition | A precise description of the patient population, anatomical site, and clinical context for which a device is validated. | A general statement defining the medical purpose of the device, including the disease or condition it diagnoses, treats, or prevents. |
Scope | Narrow and specific; defines exact clinical scenarios and patient cohorts. | Broad and general; defines the overall functional objective of the device. |
Primary Audience | Clinicians and end-users who need to know exactly when to apply the device. | FDA reviewers and regulatory bodies determining device classification and jurisdiction. |
Key Content | Patient selection criteria, anatomical site, disease stage, and clinical setting. | The general medical purpose, mechanism of action, and high-level clinical benefit. |
Regulatory Impact | Directly constrains labeling, marketing claims, and clinical validation study design. | Determines device classification, regulatory pathway, and applicable standards. |
FDA Submission Role | Appears on the FDA Form 3514 and defines the boundaries of cleared claims. | Establishes whether a product meets the definition of a medical device under Section 201(h) of the FD&C Act. |
Modification Sensitivity | Any expansion requires a new 510(k) or PMA supplement with supporting clinical data. | Minor clarifications may not require a new submission; major changes can trigger reclassification. |
Relationship to Labeling | Must be verbatim consistent with the Indications section of device labeling. | Informs the overall labeling narrative but is not required to appear verbatim. |
INDICATIONS FOR USE
Frequently Asked Questions
Clarifying the precise scope and regulatory boundaries of a medical device's validated clinical application.
An Indication for Use (IFU) statement is a precise, formal declaration that defines the patient population, anatomical site, disease or condition, and clinical context for which a Software as a Medical Device (SaMD) has been validated. It serves as the legal boundary of a device's cleared marketing authorization. Unlike the broader Intended Use Statement, which describes the general purpose, the IFU specifies the exact clinical scenario. For example, an IFU might state: "For use by radiologists to detect and localize suspicious lesions in screening mammograms for asymptomatic women over 40." This statement directly determines the required clinical evidence, the scope of the 510(k) Premarket Notification, and the labeling that appears on the device.
Enabling Efficiency, Speed & Accuracy
Intelligent Analysis, Decision & Execution
We build AI systems for teams that need search across company data, workflow automation across tools, or AI features inside products and internal software.
Talk to Us
Search across company data
Give teams answers from docs, tickets, runbooks, and product data with sources and permissions.
Useful when people spend too long searching or get different answers from different systems.
Enterprise searchRAGPermissions
Read more
Automate internal workflows
Use AI to route work, draft outputs, trigger actions, and keep approvals and logs in place.
Useful when repetitive work moves across multiple tools and teams.
AI agentsWorkflow automationGovernance
Read more
Add AI to products and internal tools
Build assistants, guided actions, or decision support into the software your team or customers already use.
Useful when AI needs to be part of the product, not a separate tool.
AI integrationDecision supportModel routing
Read more
About the author
Prasad Kumkar
CEO & MD, Inference Systems
Prasad Kumkar is the CEO & MD of Inference Systems and writes about AI systems architecture, LLM infrastructure, model serving, evaluation, and production deployment. Over 5+ years, he has worked across computer vision models, L5 autonomous vehicle systems, and LLM research, with a focus on taking complex AI ideas into real-world engineering systems.
His work and writing cover AI systems, large language models, AI agents, multimodal systems, autonomous systems, inference optimization, RAG, evaluation, and production AI engineering.
LinkedIn
Limited slotsGet a Free AI Consultation
Partnered with leading AI, data, and software stack.
How We Work
Custom AI workflows for your Business
One-fit-all AI don't work for modern businesses. At Inferensys, we aim to understand your business & custom requirements; which we use to define most efficient agentic workflows, the data, and the tools for your business.
01
Review the use case
We understand the task, the users, and where AI can actually help.
Read more02
Pick the right approach
We define what needs search, automation, or product integration.
Read more03
Build the first useful version
We implement the part that proves the value first.
Read more04
Improve from there
We add the checks and visibility needed to keep it useful.
Read moreThe first call is a practical review of your use case and the right next step.
Talk to Us